Taboola Teams with DeepIntent, Empowering More Pharma Advertisers to Reach Massive Scale on Premium Publishers

NEW YORK, September 11, 2023 — Taboola (Nasdaq: TBLA), a global leader in powering recommendations for the open web, today announced a new partnership with DeepIntent, a technology company with an advertising platform built purposefully for the healthcare industry.

Taboola partners with more than 9,000 publishers, reaching nearly 600 million daily active users and with today’s news, pharma advertisers partnering with DeepIntent will gain access to a diverse range of premium digital platforms, ensuring their messages are displayed in brand-safe and contextually relevant environments.

According to recent research conducted by Taboola and Kantar, native ads outperformed other channels at boosting mid-funnel KPIs and exceeded various marketing objectives, such as building brand awareness, consideration, brand favorability, and message association. With Taboola, DeepIntent’s extensive portfolio of hundreds of pharmaceutical brands and leading healthcare agencies can tap into these benefits, driving results for nearly any marketing objective.

“Surveying patients four separate times, we’ve consistently found that relevant pharma ads have the power to inspire action, whether that’s taking a healthcare provider’s advice or making an appointment to see one in the first place. More than ever before, we see and hear that healthcare marketers are craving performance from their marketing investments,” said Chris Paquette, Founder and CEO of DeepIntent. “With our pharma-specific solutions, Taboola ensures their advertisers are serving the most relevant ads, improving their bottom line while improving patient outcomes.”